<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Interaction between malaria and Ebola drugs and 1Q2W of COVID-19 with site 1 of COVID-19 protease (PDB code = 1Q2W)</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Drug name</th>
    <th align="left">Ligand</th>
    <th align="left">Receptor</th>
    <th align="left">Interaction</th>
    <th align="left">Distance</th>
    <th align="left">E (kcal/mol)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Atovaquone</td>
    <td align="left">6-ring</td>
    <td align="left">CD PRO 122 (B)</td>
    <td align="left">pi-H</td>
    <td align="left">4.11</td>
    <td align="left">− 0.5</td>
   </tr>
   <tr>
    <td align="left" rowspan="3">Chloroquine</td>
    <td align="left">O 5</td>
    <td align="left">NZ LYS 5 (A)</td>
    <td align="left">H-acceptor</td>
    <td align="left">3.34</td>
    <td align="left">− 0.9</td>
   </tr>
   <tr>
    <td align="left">6-ring</td>
    <td align="left">CB LYS 137 (A)</td>
    <td align="left">pi-H</td>
    <td align="left">4.16</td>
    <td align="left">− 0.6</td>
   </tr>
   <tr>
    <td align="left">6-ring</td>
    <td align="left">CA GLY 2 (B)</td>
    <td align="left">pi-H</td>
    <td align="left">3.49</td>
    <td align="left">− 0.5</td>
   </tr>
   <tr>
    <td align="left">Doxycycline</td>
    <td align="left">N 6</td>
    <td align="left">N GLN 127 (A)</td>
    <td align="left">H-acceptor</td>
    <td align="left">3.27</td>
    <td align="left">− 3.2</td>
   </tr>
   <tr>
    <td align="left">Mefloquine</td>
    <td align="left">O 41</td>
    <td align="left">OG1 THR 285 (A)</td>
    <td align="left">H-donor</td>
    <td align="left">3.09</td>
    <td align="left">− 0.9</td>
   </tr>
   <tr>
    <td align="left" rowspan="2">Primaquine</td>
    <td align="left">F 1</td>
    <td align="left">N GLN 127 (B)</td>
    <td align="left">H-acceptor</td>
    <td align="left">3.05</td>
    <td align="left">− 0.6</td>
   </tr>
   <tr>
    <td align="left">6-ring</td>
    <td align="left">CG LYS 5 (B)</td>
    <td align="left">pi-H</td>
    <td align="left">3.72</td>
    <td align="left">− 0.8</td>
   </tr>
   <tr>
    <td align="left" rowspan="2">Tafenoquine</td>
    <td align="left">N 27</td>
    <td align="left">NH1 ARG 4 (B)</td>
    <td align="left">H-acceptor</td>
    <td align="left">3.58</td>
    <td align="left">− 1.6</td>
   </tr>
   <tr>
    <td align="left">6-ring</td>
    <td align="left">CD LYS 5 (A)</td>
    <td align="left">pi-H</td>
    <td align="left">4.49</td>
    <td align="left">− 0.7</td>
   </tr>
   <tr>
    <td align="left" rowspan="2">Favipiravir</td>
    <td align="left">N 13</td>
    <td align="left">O LYS 5 (A)</td>
    <td align="left">H-donor</td>
    <td align="left">3.16</td>
    <td align="left">− 1.6</td>
   </tr>
   <tr>
    <td align="left">N 9</td>
    <td align="left">N GLN 127 (B)</td>
    <td align="left">H-acceptor</td>
    <td align="left">3.32</td>
    <td align="left">− 2.3</td>
   </tr>
   <tr>
    <td align="left" rowspan="5">Ribavirin</td>
    <td align="left">O 1</td>
    <td align="left">O PHE 3 (B)</td>
    <td align="left">H-donor</td>
    <td align="left">2.98</td>
    <td align="left">− 0.8</td>
   </tr>
   <tr>
    <td align="left">O 15</td>
    <td align="left">NZ LYS 5 (A)</td>
    <td align="left">H-acceptor</td>
    <td align="left">3.26</td>
    <td align="left">− 1.2</td>
   </tr>
   <tr>
    <td align="left">O 26</td>
    <td align="left">N GLN 127 (B)</td>
    <td align="left">H-acceptor</td>
    <td align="left">3.14</td>
    <td align="left">− 3.2</td>
   </tr>
   <tr>
    <td align="left">N 27</td>
    <td align="left">N GLN 127 (A)</td>
    <td align="left">H-acceptor</td>
    <td align="left">3.32</td>
    <td align="left">− 2.1</td>
   </tr>
   <tr>
    <td align="left">5-ring</td>
    <td align="left">CB LYS 5 (B)</td>
    <td align="left">pi-H</td>
    <td align="left">3.99</td>
    <td align="left">− 0.7</td>
   </tr>
   <tr>
    <td align="left" rowspan="4">Galidesivir</td>
    <td align="left">O 33</td>
    <td align="left">O PHE 3 (B)</td>
    <td align="left">H-donor</td>
    <td align="left">3.00</td>
    <td align="left">− 1.2</td>
   </tr>
   <tr>
    <td align="left">N 9</td>
    <td align="left">NH1 ARG 4 (B)</td>
    <td align="left">H-acceptor</td>
    <td align="left">3.25</td>
    <td align="left">− 4.0</td>
   </tr>
   <tr>
    <td align="left">N 12</td>
    <td align="left">N GLN 127 (A)</td>
    <td align="left">H-acceptor</td>
    <td align="left">3.59</td>
    <td align="left">− 1.0</td>
   </tr>
   <tr>
    <td align="left">6-ring</td>
    <td align="left">CD LYS 5 (A)</td>
    <td align="left">pi-H</td>
    <td align="left">4.39</td>
    <td align="left">− 0.7</td>
   </tr>
   <tr>
    <td align="left" rowspan="2">Brincidovir</td>
    <td align="left">O 63</td>
    <td align="left">O GLN 127 (B)</td>
    <td align="left">H-donor</td>
    <td align="left">3.02</td>
    <td align="left">− 2.9</td>
   </tr>
   <tr>
    <td align="left">O 68</td>
    <td align="left">NH1 ARG 4 (A)</td>
    <td align="left">H-acceptor</td>
    <td align="left">2.95</td>
    <td align="left">− 2.4</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
